Physician profile
Peter V Pickens
NPI 1528078698
$2,727.27
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,826 · 2020: $140 · 2021: $185 · 2022: $237 · 2023: $146 · 2024: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $318.91 | 2019-2024 | Reblozyl |
| Dova Pharmaceuticals | $252.51 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $245.15 | 2019 | |
| Abbvie INC. | $215.06 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.36 | 2019-2023 | |
| Glaxosmithkline, LLC. | $174.61 | 2021-2024 | Ojjaara |
| Akcea Therapeutics, INC. | $151.23 | 2019 | |
| Amgen INC. | $109.26 | 2019-2020 | |
| Genentech USA, INC. | $100.89 | 2019-2020 | |
| Pfizer INC. | $95.36 | 2019 | |
| Janssen Biotech, INC. | $83.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $66.07 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $63.02 | 2019-2023 | Imbruvica |
| Genzyme Corporation | $58.74 | 2019 | |
| Emmaus Medical, INC. | $58.44 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $58.43 | 2019-2020 | |
| Kite Pharma, INC. | $51.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $47.93 | 2019 | |
| Sobi, INC | $44.68 | 2022 | |
| Jazz Pharmaceuticals INC. | $43.28 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $37.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.26 | 2019 | |
| Aurobindo Pharma USA, INC. | $24.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.38 | 2019 | |
| Verastem, INC. | $23.06 | 2020 | |
| Eisai INC. | $19.84 | 2019 | |
| Merck Sharp & Dohme LLC | $18.49 | 2019 | |
| Gilead Sciences, INC. | $18.29 | 2019 | |
| Shire North American Group INC | $16.67 | 2019 | |
| Karyopharm Therapeutics INC. | $16.56 | 2020 | |
| Amag Pharmaceuticals, INC. | $16.30 | 2019 | |
| Clovis Oncology, INC. | $16.16 | 2019 | |
| Emd Serono, INC. | $15.78 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.46 | 2019 | |
| Incyte Corporation | $12.89 | 2019 | |
| Clinigen, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Pickens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.